Cargando…
Interaction Between SARS-CoV-2 and Pathogenic Bacteria
The novel human coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which results in the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. Therefore, many studies are performed on the causes and prevalence of this disease and the possibl...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206355/ https://www.ncbi.nlm.nih.gov/pubmed/37222840 http://dx.doi.org/10.1007/s00284-023-03315-y |
_version_ | 1785046211605037056 |
---|---|
author | Fazel, Parvindokht Sedighian, Hamid Behzadi, Elham Kachuei, Reza Imani Fooladi, Abbas Ali |
author_facet | Fazel, Parvindokht Sedighian, Hamid Behzadi, Elham Kachuei, Reza Imani Fooladi, Abbas Ali |
author_sort | Fazel, Parvindokht |
collection | PubMed |
description | The novel human coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which results in the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. Therefore, many studies are performed on the causes and prevalence of this disease and the possible co-occurrence of the infection with other viral and bacterial pathogens is investigated. Respiratory infections predispose patients to co‐infections and these lead to increased disease severity and mortality. Numerous types of antibiotics have been employed for the prevention and treatment of bacterial co‐infection and secondary bacterial infections in patients with a SARS-CoV-2 infection. Although antibiotics do not directly affect SARS‐CoV‐2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co‐infection rather than virus itself. Therefore, bacterial co‐infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID‐19. In this review, we will summarize the bacterial co‐infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID‐19. |
format | Online Article Text |
id | pubmed-10206355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-102063552023-05-25 Interaction Between SARS-CoV-2 and Pathogenic Bacteria Fazel, Parvindokht Sedighian, Hamid Behzadi, Elham Kachuei, Reza Imani Fooladi, Abbas Ali Curr Microbiol Review Article The novel human coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which results in the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. Therefore, many studies are performed on the causes and prevalence of this disease and the possible co-occurrence of the infection with other viral and bacterial pathogens is investigated. Respiratory infections predispose patients to co‐infections and these lead to increased disease severity and mortality. Numerous types of antibiotics have been employed for the prevention and treatment of bacterial co‐infection and secondary bacterial infections in patients with a SARS-CoV-2 infection. Although antibiotics do not directly affect SARS‐CoV‐2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co‐infection rather than virus itself. Therefore, bacterial co‐infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID‐19. In this review, we will summarize the bacterial co‐infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID‐19. Springer US 2023-05-24 2023 /pmc/articles/PMC10206355/ /pubmed/37222840 http://dx.doi.org/10.1007/s00284-023-03315-y Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Fazel, Parvindokht Sedighian, Hamid Behzadi, Elham Kachuei, Reza Imani Fooladi, Abbas Ali Interaction Between SARS-CoV-2 and Pathogenic Bacteria |
title | Interaction Between SARS-CoV-2 and Pathogenic Bacteria |
title_full | Interaction Between SARS-CoV-2 and Pathogenic Bacteria |
title_fullStr | Interaction Between SARS-CoV-2 and Pathogenic Bacteria |
title_full_unstemmed | Interaction Between SARS-CoV-2 and Pathogenic Bacteria |
title_short | Interaction Between SARS-CoV-2 and Pathogenic Bacteria |
title_sort | interaction between sars-cov-2 and pathogenic bacteria |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206355/ https://www.ncbi.nlm.nih.gov/pubmed/37222840 http://dx.doi.org/10.1007/s00284-023-03315-y |
work_keys_str_mv | AT fazelparvindokht interactionbetweensarscov2andpathogenicbacteria AT sedighianhamid interactionbetweensarscov2andpathogenicbacteria AT behzadielham interactionbetweensarscov2andpathogenicbacteria AT kachueireza interactionbetweensarscov2andpathogenicbacteria AT imanifooladiabbasali interactionbetweensarscov2andpathogenicbacteria |